Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1160775 | 0.98 | PTPN1 (0.62) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6677659 | 0.93 | PTPN1 (0.65) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL24892329 | 0.91 | PLAU (0.69) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL28241907 | 0.88 | NR1H4 (0.77) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8185226 | 0.86 | MEN1 (0.62) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5154816 | 0.85 | PTPN1 (0.69) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6681834 | 0.85 | KCNK3 (0.69) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL19964495 | 0.85 | LOXL2 (0.62) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL27918535 | 0.85 | MEN1 (0.50) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL126415 | 0.84 | PTPN1 (0.87) | PTPN1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | NAN Global, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| CN-110483582-A | Azepine Cabbeen palladium complex crystal and its synthetic method and preparing the application in amide compound | UNIV SHAANXI NORMAL | 2019-11-22 | — | — | CN | disclosed |
| CN-107652200-B | A method of N- aryl Zhong Fang amide is synthesized using aryl hydrazine | 陕西科技大学 | 2019-06-14 | — | — | CN | disclosed |
| CN-107652200-A | A kind of method that N aryl Zhong Fang acid amides is synthesized using aryl hydrazine | 陕西科技大学 | 2018-02-02 | — | — | CN | disclosed |
| CN-104961777-B | Rare earth/sodium mixed bimetal complex and preparation method and application thereof | 安徽大学 | 2017-10-31 | — | — | CN | disclosed |
| CN-105669491-B | A kind of acylation method of amine | 苏州大学 | 2017-10-13 | — | — | CN | disclosed |
| CN-105669491-A | Acidylation method of amine | 苏州大学 | 2016-06-15 | — | — | CN | disclosed |
| CN-104961777-A | Rare earth/sodium mixed bimetal complex and preparation method and application thereof | UNIV ANHUI | 2015-10-07 | — | — | CN | disclosed |
| CN-103214386-B | New method for synthesizing amide compounds | UNIV QINGDAO AGRICULTURAL | 2014-08-13 | — | — | CN | disclosed |
| CN-103214386-A | New method for synthesizing amide compounds | UNIV QINGDAO AGRICULTURAL | 2013-07-24 | — | — | CN | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003057205-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
| EP-1301464-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-04-16 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| WO-2003004020-A1 | HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-16 | — | — | WO | disclosed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | PTPN1 770/4885NPC1 32/4885RAB9A 4424/4885 |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | PTPN1 1922/4885NPC1 63/4885RAB9A 4376/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | PTPN1 1172/4885NPC1 120/4885RAB9A 3035/4885 |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | GPR119, CPT1B, CPT2 | PTPN1 1472/4885NPC1 3146/4885RAB9A 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.